JP2007519703A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007519703A5 JP2007519703A5 JP2006550330A JP2006550330A JP2007519703A5 JP 2007519703 A5 JP2007519703 A5 JP 2007519703A5 JP 2006550330 A JP2006550330 A JP 2006550330A JP 2006550330 A JP2006550330 A JP 2006550330A JP 2007519703 A5 JP2007519703 A5 JP 2007519703A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- composition according
- pharmaceutical composition
- preservative
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229920000858 Cyclodextrin Polymers 0.000 claims 6
- 230000002335 preservative effect Effects 0.000 claims 6
- 239000003755 preservative agent Substances 0.000 claims 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims 3
- 239000001116 FEMA 4028 Substances 0.000 claims 2
- 229940122540 Neurokinin receptor antagonist Drugs 0.000 claims 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 2
- 229960004853 betadex Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002462 tachykinin receptor antagonist Substances 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940100630 metacresol Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960003742 phenol Drugs 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical group [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 1
- 229940033663 thimerosal Drugs 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54089704P | 2004-01-30 | 2004-01-30 | |
| US60/540,897 | 2004-01-30 | ||
| PCT/IB2005/000100 WO2005082416A2 (en) | 2004-01-30 | 2005-01-17 | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007519703A JP2007519703A (ja) | 2007-07-19 |
| JP2007519703A5 true JP2007519703A5 (enExample) | 2007-11-29 |
| JP5021318B2 JP5021318B2 (ja) | 2012-09-05 |
Family
ID=34910697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006550330A Expired - Lifetime JP5021318B2 (ja) | 2004-01-30 | 2005-01-17 | β−シクロデキストリンを液体投薬形態に用いて多用量製剤を達成するための抗菌性防腐剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8183230B2 (enExample) |
| EP (1) | EP1713504B1 (enExample) |
| JP (1) | JP5021318B2 (enExample) |
| KR (1) | KR100834232B1 (enExample) |
| CN (1) | CN101090735A (enExample) |
| AR (2) | AR047469A1 (enExample) |
| AU (1) | AU2005216709B2 (enExample) |
| BR (1) | BRPI0506496B8 (enExample) |
| CA (1) | CA2554346C (enExample) |
| CO (1) | CO5700794A2 (enExample) |
| CY (1) | CY1119188T1 (enExample) |
| DK (1) | DK1713504T3 (enExample) |
| ES (1) | ES2638113T3 (enExample) |
| HU (1) | HUE034099T2 (enExample) |
| IL (1) | IL176676A0 (enExample) |
| LT (1) | LT1713504T (enExample) |
| NO (1) | NO20063858L (enExample) |
| NZ (1) | NZ548236A (enExample) |
| PL (1) | PL1713504T3 (enExample) |
| PT (1) | PT1713504T (enExample) |
| RU (1) | RU2332997C2 (enExample) |
| SI (1) | SI1713504T1 (enExample) |
| TW (1) | TW200524632A (enExample) |
| WO (1) | WO2005082416A2 (enExample) |
| ZA (1) | ZA200605148B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101922752B1 (ko) | 2011-11-29 | 2018-11-27 | 주록스 피티와이 리미티드 | 사이클로덱스트린 및 소수성 약물을 포함하는 주사용 약제학적 조성물을 보존하는 방법 |
| AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
| EP3865120B1 (en) * | 2013-07-19 | 2025-06-25 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| WO2015082389A1 (en) | 2013-12-04 | 2015-06-11 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
| EA202090180A1 (ru) | 2017-06-30 | 2020-05-26 | Чейс Терапьютикс Корпорейшн | Композиции nk1-антагониста и способы лечения депрессии |
| MX2021009777A (es) * | 2019-02-15 | 2021-12-15 | Saol Int Development Ltd | Formulaciones inyectables de fenol y metodos de su uso. |
| EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
| CN112370451A (zh) * | 2020-12-08 | 2021-02-19 | 河北科技大学 | 一种枸橼酸马罗匹坦包合物、注射液及制备方法 |
| AT527172A1 (de) * | 2023-04-25 | 2024-11-15 | Vetviva Richter Gmbh | Maropitantformulierung |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5910510A (ja) * | 1982-07-08 | 1984-01-20 | Nippon Zenyaku Kogyo Kk | 低刺激性チアムリン注射剤 |
| JPS59152320A (ja) * | 1983-02-17 | 1984-08-31 | Takeda Chem Ind Ltd | 水性製剤 |
| JPS6419737A (en) * | 1987-07-15 | 1989-01-23 | Hitachi Ltd | Multilayer interconnection tape carrier |
| JPH039848A (ja) * | 1989-06-06 | 1991-01-17 | Canon Inc | 液体噴射記録装置 |
| DE122006000066I2 (de) * | 1991-05-31 | 2007-12-06 | Pfizer | Chinuclidinderivate |
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| ES2096312T3 (es) * | 1992-11-12 | 1997-03-01 | Pfizer | Derivado de quinuclidina como antagonista de la sustancia p. |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| CA2342797A1 (en) | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| US6255320B1 (en) * | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| AU5975700A (en) * | 1999-07-02 | 2001-01-22 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| CA2441744C (en) * | 2001-03-20 | 2011-07-12 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| HUP0401154A2 (hu) * | 2001-07-20 | 2004-10-28 | Pfizer Products Inc. | NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására |
| AU2003218059A1 (en) * | 2002-02-22 | 2003-09-09 | Pharmacia Corporation | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| DE10228049A1 (de) | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
| US6861526B2 (en) * | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
| AU2005216707A1 (en) | 2004-01-30 | 2005-09-09 | Pfizer Products Inc. | Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration |
| JP2007519701A (ja) | 2004-01-30 | 2007-07-19 | ファイザー・プロダクツ・インク | 麻酔回復を改善するためのnk−1受容体拮抗剤 |
| PT1713801E (pt) | 2004-02-02 | 2008-02-11 | Pfizer Prod Inc | Processo para a preparação de 1-(2s,3s)-2-benzidril-n-(5- -terc-butil-2-metoxibenzil)-quinuclidina-3-amina |
-
2005
- 2005-01-17 KR KR1020067015283A patent/KR100834232B1/ko not_active Expired - Lifetime
- 2005-01-17 HU HUE05702263A patent/HUE034099T2/en unknown
- 2005-01-17 EP EP05702263.4A patent/EP1713504B1/en not_active Expired - Lifetime
- 2005-01-17 BR BRPI0506496A patent/BRPI0506496B8/pt active IP Right Grant
- 2005-01-17 NZ NZ548236A patent/NZ548236A/en not_active IP Right Cessation
- 2005-01-17 RU RU2006127422/15A patent/RU2332997C2/ru not_active IP Right Cessation
- 2005-01-17 PL PL05702263T patent/PL1713504T3/pl unknown
- 2005-01-17 PT PT57022634T patent/PT1713504T/pt unknown
- 2005-01-17 WO PCT/IB2005/000100 patent/WO2005082416A2/en not_active Ceased
- 2005-01-17 JP JP2006550330A patent/JP5021318B2/ja not_active Expired - Lifetime
- 2005-01-17 SI SI200532166T patent/SI1713504T1/sl unknown
- 2005-01-17 DK DK05702263.4T patent/DK1713504T3/en active
- 2005-01-17 CN CNA2005800032849A patent/CN101090735A/zh active Pending
- 2005-01-17 ES ES05702263.4T patent/ES2638113T3/es not_active Expired - Lifetime
- 2005-01-17 LT LTEP05702263.4T patent/LT1713504T/lt unknown
- 2005-01-17 US US10/588,070 patent/US8183230B2/en active Active
- 2005-01-17 CA CA002554346A patent/CA2554346C/en not_active Expired - Lifetime
- 2005-01-17 AU AU2005216709A patent/AU2005216709B2/en not_active Expired
- 2005-01-27 AR ARP050100283A patent/AR047469A1/es not_active Application Discontinuation
- 2005-01-28 TW TW094102680A patent/TW200524632A/zh unknown
-
2006
- 2006-06-22 ZA ZA200605148A patent/ZA200605148B/en unknown
- 2006-07-03 IL IL176676A patent/IL176676A0/en unknown
- 2006-07-26 CO CO06073023A patent/CO5700794A2/es not_active Application Discontinuation
- 2006-08-29 NO NO20063858A patent/NO20063858L/no not_active Application Discontinuation
-
2017
- 2017-08-04 CY CY20171100843T patent/CY1119188T1/el unknown
- 2017-08-16 AR ARP170102291A patent/AR109357A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019131596A5 (enExample) | ||
| RU2470016C2 (ru) | Производное бипиразола | |
| US20050085446A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| JP2010504973A5 (enExample) | ||
| JP2009502743A5 (enExample) | ||
| WO2005097125A3 (en) | Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease | |
| JP2009102342A5 (enExample) | ||
| JP2007519703A5 (enExample) | ||
| JP2012508734A5 (enExample) | ||
| NZ604983A (en) | Dry powder formulation comprising an antimuscarinic drug | |
| JP2014521641A5 (enExample) | ||
| JP2008513510A5 (enExample) | ||
| CN114364402A (zh) | 用于治疗癌症的阿片类生长因子受体(ogfr)拮抗剂,特别是纳洛酮和/或纳曲酮 | |
| JP2011046708A5 (enExample) | ||
| JP2012508256A5 (enExample) | ||
| RU2006127422A (ru) | Антимикробные консерванты для достижения мультидозовых рецептур с использованием бета-циклодекстринов для жидких лекарственных форм | |
| JP2010510194A5 (enExample) | ||
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| JP2010500284A5 (enExample) | ||
| US20070049552A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| ES2702578T3 (es) | Tratamiento de la inflamación dérmica crónica con norketotifeno | |
| JP2007530703A5 (enExample) | ||
| JP2014534229A5 (enExample) | ||
| JP7110196B2 (ja) | カルバメート化合物を含む非経口用液剤 | |
| JP2008533079A5 (enExample) |